Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema

Rhea-AI Summary

Tactile Medical (NASDAQ: TCMD) has expanded the availability of its Nimbl™ pneumatic compression device to include treatment for lower extremity lymphedema across the United States. This expansion follows the initial October 2024 launch for upper extremity lymphedema treatment.

The Nimbl device represents significant technological advancement, being 68% lighter and 40% smaller than the company's current generation PCD, with 94% less hosing in its lower extremity garment. It is the only basic PCD featuring Bluetooth® connectivity, allowing patients to track treatments and symptoms through the free Kylee™ digital application.

This expansion targets a market of 16 million Americans with chronic swelling in lower extremities, offering them a more portable and user-friendly treatment option designed to improve patient adherence and care experience.

Positive

• Expanded market reach to 16 million potential patients with lower extremity conditions
• Significant product improvements: 68% lighter, 40% smaller than previous generation
• Unique feature advantage with Bluetooth connectivity and digital tracking app
• Enhanced portability with 94% less hosing in lower extremity garment

Negative

• None.

Next-Generation Platform Now Available for Both Upper and Lower Extremity Conditions

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl’s expanded availability to include lower extremity conditions (“phlebolymphedema”) follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema.

“On the heels of Nimbl’s launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 million Americans with chronic swelling in the lower extremities,” said Sheri Dodd, Chief Executive Officer at Tactile Medical. “These patients require effective, convenient therapies to help manage their symptoms. With Nimbl, they now have access to a solution which embodies patient-focused innovation and reflects our commitment to serving patients and improving their care experience.”

Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company’s current generation PCD. The lower extremity garment uses 94% less hosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth^® connectivity, providing patients a way to track their treatments and symptom progress with the Company’s free Kylee™ digital application.

“Nimbl for lower extremity lymphedema is intentionally designed as a user-friendly, patient-centric treatment option that is comfortable, clinically effective, and optimized for increased adherence,” said Tony Gasparis, MD, Chief Medical Officer at Tactile Medical. “Its physical dimensions and significant reduction in hose length afford patients the ability to more easily transport Nimbl around the home, or take it with them when traveling, providing an improved all around patient experience.”

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com

FAQ

What are the key features of Tactile Medical's new Nimbl device for lymphedema (TCMD)?

Nimbl is 68% lighter and 40% smaller than previous models, uses 94% less hosing for lower extremity treatment, and is the only basic PCD with Bluetooth connectivity for treatment tracking via the Kylee™ app.

When did Tactile Medical (TCMD) expand Nimbl's availability to lower extremity lymphedema?

Tactile Medical expanded Nimbl's availability to lower extremity lymphedema in February 2024, following its initial October 2024 launch for upper extremity treatment.

How many potential patients could benefit from TCMD's Nimbl lower extremity treatment?

According to Tactile Medical, 16 million Americans with chronic swelling in lower extremities could potentially benefit from the Nimbl treatment.

What digital capabilities does TCMD's Nimbl device offer for patient monitoring?

Nimbl features Bluetooth connectivity that works with the free Kylee™ digital application, allowing patients to track their treatments and symptom progress.